Abaloparatide

Muscle/RecoveryFDA-approved PTHrP analogEstablished

FDA-approved parathyroid hormone–related peptide analog (Tymlos) for postmenopausal osteoporosis at high fracture risk. Daily 80 mcg subcutaneous injection; treatment typically limited to 2 years.

Calculate Dose

For research use only.

Key Facts

CAS: 247062-33-5
Molecular Weight (MW): 3961.6 g/mol
Half-life: ~1–1.7 hours
Unit: mcg
Administration Route: Subcutaneous
Frequency: Once daily
Last updated: 8/23/2026
Targets: PTH1 receptorOsteoblasts

Overview

FDA-approved parathyroid hormone–related peptide analog (Tymlos) for postmenopausal osteoporosis at high fracture risk. Daily 80 mcg subcutaneous injection; treatment typically limited to 2 years.

Protocol

Dosage Range: 80 mcg daily (labeled)
Frequency: Once daily
Cycle: Maximum 2 years of treatment
Administration Route: Subcutaneous
Reconstitution Guide: Prefilled pen — no reconstitution

Science

Mechanism of Action

Selective PTH1 receptor agonist that stimulates osteoblastic bone formation, increasing bone mineral density and reducing vertebral and nonvertebral fracture risk.